MedTrace Logo

Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer

NCT05893966 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-06-29

No results posted yet for this study

Summary

The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.

The main questions it aims to answer are:

* 7-year ipsilateral breast tumor recurrence
* 7-year disease-free survival
* 7-year locoregional recurrence
* 7-year overall survival
* Adverse events of radiation therapy

Participants will be assessed by multi-dimensional methods after radiation therapy:

* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination
* Assessment for the adverse events according to CTCAE version 5.0

Conditions

Interventions

RADIATION

Whole breast irradiation +/- tumor bed boost

Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Haeyoung Kim, MD, PhD · Samsung Medical Center

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2025-11-29
Completion
2032-11-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05893966 on ClinicalTrials.gov